TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04093999

Intervention type: PROCEDURE
Intervention: Sensory nerve coaptation
Description: A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
Study: NCT02661477

Intervention type: DRUG
Group type: OTHER
Intervention: pegylated interferon alfa 2

Intervention type: DRUG
Group type: OTHER
Intervention: pegylated interferon alfa 2

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0,9% natrium chlorine solution

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0,9% natrium chlorine solution
Study: NCT02287519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching Session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webinar
Study: NCT03559309

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing
Description: Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
Study: NCT05484947

Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa HIV testing
Description: HIV testing on a voluntary basis

Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa HIV testing
Description: HIV testing on a voluntary basis
Study: NCT04281719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application (working name: Bright Path)
Description: The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
Study: NCT00872157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMTP-11
Description: Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
Study: NCT04183673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy-cryo thermal therapy
Description: 5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
Study: NCT01334853

Intervention type: OTHER
Intervention: No drug will be used
Description: Biomarker

Intervention type: OTHER
Intervention: No drug will be used
Description: Biomarker
Study: NCT03718260

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
Study: NCT02659293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: * Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: * Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22
Study: NCT01998607

Intervention type: OTHER
Intervention: Physician Survey
Description: Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
Study: NCT02659293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide (Control)
Description: * Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28
Study: NCT03269669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scans

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT scans

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans
Study: NCT02724033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional nerve block
Description: regional nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional nerve block
Description: regional nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic
Description: Antiemetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic
Description: Antiemetic
Study: NCT01093495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Cannula
Description: Nasal Cannula
Study: NCT03615092

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root coverage with extended flap technique and acelular dermal matrix
Description: At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage with extended flap technique and acelular dermal matrix
Description: At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
Study: NCT01671410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine
Description: Oral morphine for the treatment of neonatal abstinence syndrome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine
Description: Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
Study: NCT05527925

Intervention type: DEVICE
Intervention: MRI
Description: Brain testing of patients using MRI

Intervention type: DEVICE
Intervention: MRI
Description: Brain testing of patients using MRI

Intervention type: DEVICE
Intervention: MRI
Description: Brain testing of patients using MRI

Intervention type: DEVICE
Intervention: MRI
Description: Brain testing of patients using MRI
Study: NCT04234438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)
Description: Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)
Description: Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
Study: NCT03317587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INSPIRE
Description: Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
Study: NCT00257127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent conjugate vaccine
Description: 0.5 mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Description: 0.5 mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: 0.5 mL administered intramuscularly
Study: NCT03269669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study: NCT00257127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: 0.5 mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella virus vaccine, live
Description: 0.5 mL administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella virus vaccine, live
Description: 0.5 mL administered subcutaneously
Study: NCT00427414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal daunorubicin citrate
Description: 40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
Study: NCT01179295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 30 mg twice a day (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 50 mg twice a day (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 100 mg once a day (od)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 60 mg once a day (od)
Study: NCT00290472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Study: NCT02488278

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: GlucoMe Glucose Monitoring Device
Description: Perform a blood glucose test using the application and device
Study: NCT04507815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
Study: NCT03175523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quantitative coronary angiography guided Bioresorbable scaffold implantation
Description: In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging guided Bioresorbable scaffold implantation
Description: In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
Study: NCT04146558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized internal ayurvedic treatment
Description: All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External ayurvedic treatment
Description: Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
Study: NCT00997074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
Study: NCT04408456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCQ
Description: Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: Home quarantine for 2 weeks plus social distancing plus personal hygiene

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Home quarantine for 2 weeks plus social distancing plus personal hygiene
Study: NCT03269669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03242213

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App
Description: The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
Study: NCT05049746

Intervention type: OTHER
Group type: OTHER
Intervention: Discussion
Description: Participate in discussion

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Participate in interview
Study: NCT02607527

Intervention type: DEVICE
Group type: OTHER
Intervention: Mitral Valve IRIS Ring
Description: Transcatheter implantation of the IRIS
Study: NCT05049746

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT03342157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senna/docusate
Description: Stimulant laxative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senna/docusate
Description: Stimulant laxative
Study: NCT03718260

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyL PET/ CT scan (PSMA PET)
Description: Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
Study: NCT02887339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Website
Description: Additional training website can be found at gtextraing.org

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard training given by OPOs and GTEx staff
Study: NCT03428386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric plication ileal bypass
Description: laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
Study: NCT03672318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR138 T Cells
Description: The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days.
Study: NCT03511365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic Formulation VSL#3
Description: Probiotic VSL#3 administration.
Study: NCT01023282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR325
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACR325
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Study: NCT00803556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvespimycin
Description: Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvespimycin
Description: Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
Study: NCT01627145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin 5 mg qd,